SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Alpha Tau Medical Ltd. (DRTS) has a negative trailing P/E of -14.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 3,559.1 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -6.87%, forward earnings yield 0.03%. PEG 1.75.
Criteria proven by this page:
- VALUE (94/100, Pass) — analyst target implies upside (+53.3%).
- Forward P/E 3,559.1 — analysts expect a return to profitability with estimated EPS of $0.00 for FY2028.
- PEG Ratio 1.75 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield -6.87% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.03% as earnings recover.
- Analyst consensus target $12.00 (+53.3% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
94/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DRTS
Valuation Multiples
P/E (TTM)-14.6
Forward P/E3,559.1
PEG Ratio1.75
Forward PEG1.75
P/B Ratio8.05
P/S Ratio0.00
EV/EBITDA-15.3
Per Share Data
EPS (TTM)$-0.50
Forward EPS (Est.)$0.00
Book Value / Share$0.90
Revenue / Share$0.00
FCF / Share$-0.38
Yields & Fair Value
Earnings Yield-6.87%
Forward Earnings Yield0.03%
Dividend Yield0.00%
Analyst Target$12.00 (+53.3%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-80.7 |
0.00 |
-3,538.74 |
0.00 |
- |
| 2020 |
-46.0 |
-0.66 |
-48.45 |
0.00 |
- |
| 2021 |
-14.6 |
-0.07 |
-11.44 |
0.00 |
- |
| 2022 |
-6.0 |
0.29 |
1.91 |
0.00 |
- |
| 2023 |
-7.1 |
0.34 |
2.46 |
0.00 |
- |
| 2024 |
-6.8 |
-0.96 |
3.46 |
0.00 |
- |
| 2025 |
-9.4 |
-0.53 |
5.17 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.13 |
$0.00 |
$-8.46M |
- |
| 2020 |
$-0.22 |
$0.00 |
$-8.88M |
- |
| 2021 |
$-0.67 |
$0.00 |
$-27.27M |
- |
| 2022 |
$-0.53 |
$0.00 |
$-33.76M |
- |
| 2023 |
$-0.42 |
$0.00 |
$-29.16M |
- |
| 2024 |
$-0.45 |
$0.00 |
$-31.75M |
- |
| 2025 |
$-0.53 |
$0.00 |
$-42.63M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-0.51 |
$-0.54 – $-0.49 |
$1.28M |
$835.22K – $1.91M |
3 |
| 2027 |
$-0.43 |
$-0.48 – $-0.37 |
$16.52M |
$10.82M – $24.72M |
2 |
| 2028 |
$0.00 |
$0.00 – $0.00 |
$72.34M |
$72.34M – $72.34M |
1 |
| 2029 |
$0.19 |
$0.10 – $0.30 |
$125.19M |
$82.01M – $187.35M |
1 |
| 2030 |
$1.00 |
$0.55 – $1.65 |
$259.02M |
$169.68M – $387.63M |
1 |
